Anjarium Biosciences

Recent Finacing

Series A

Recent Raise

$60.3M

Anjarium Biosciences develops non-viral gene therapies using proprietary DNA-based vectors and Hybridosome nanoparticle delivery technologies, combining synthetic biology and scalable manufacturing for tissue-targeted genetic medicines.

Founded 2017

Zurich, Switzerland

1-10

Private

anjarium.com

Highlights

Focus Areas

Biotechnology

Pharmaceutical

Recent Investors

Financials

$60.3M

Total Raised

1

Funding round

5

Investors

Team

Upgrade to view the team

See the team members at Anjarium Biosciences.